Calithera Reports Phase I Data for CB-839 in Patients with Solid Tumors at the 2015 American Society of Clinical Oncology
Calithera Biosciences, Inc.
May 30, 2015 8:00 AM
GlobeNewswire
Nach der Präsentation wieder auf 9,21 Dollar gefallen, hmmmmm..
Data Support Initiation of Multiple Solid Tumor Expansion Cohorts
Calithera to Host Investor Webcast on May 30, 2015 at 6:30 p.m. CT
SOUTH SAN FRANCISCO, Calif., May 30, 2015 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (CALA), a clinical stage biotechnology company focused on the development of novel cancer therapeutics, today announced that data from its lead, first-in-class program CB-839 was presented today at the 2015 American Society of Clinical Oncology (ASCO) in Chicago, Illinois. The data demonstrate the clinical activity, tolerability and unique mechanism of action of CB-839 in patients with solid tumors.
